Tarsus Eyedrop Breakthrough Sends Stock Soaring: 10.9% Rally and Counting

Tarsus Pharmaceuticals is a biopharma focused on eye care. Its flagship product XDEMVY was FDA-approved in July 2023 as the first-ever treatment for Demodex blepharitis globenewswire.com. Tarsus reports that XDEMVY’s launch has exceeded expectations – CEO Bobak Azamian called the Q2 results their “strongest quarter to date” and emphasized XDEMVY as the new standard of care nasdaq.com. Management notes more than 20,000 eye doctors are now prescribing XDEMVY nasdaq.com, backed by national TV advertising globenewswire.com and an expanded sales team. The company now covers >90% of U.S. patients nasdaq.com, and patient engagement has surged with the marketing push nasdaq.com.